Lilly’s Dosing Scheme For Donanemab In Alzheimer’s And Treatment Cost Effectiveness

Firm’s aggressive approach to amyloid plaque removal means a shorter duration of treatment and potentially lower costs.

Treatment Halted With Plaque Clearance • Source: Shutterstock

Eli Lilly and Company believes its treatment approach for donanemab in early Alzheimer’s disease can be a cost saver that would enhance the drug’s appeal to payers.

In the company’s TRAILBLAZER ALZ-2 clinical trial, patients on donanemab were switched to placebo once they achieved substantial amyloid plaque...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet